BDTX
BDTX clinical trials: Black Diamond Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Black Diamond Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BDTX on the catalyst calendar · BDTX registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Mar 2028Sponsor estimate | NCT05256290Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsBlack Diamond Therapeutics, Inc. · Non-Small Cell Lung Cancer | BDTXLead | Phase 1/Phase 2 | Recruiting | Locked | Locked | Locked |
| Nov 2028Sponsor estimate | NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc. · Glioblastoma (GBM) | BDTXLead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Sep 2, 2022Actual | NCT04209465A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.Black Diamond Therapeutics, Inc. · Solid Tumor | BDTXLead | Phase 1 | Terminated | Locked | Locked | Locked |
- Primary completion Mar 2028Sponsor estimatePhase 1/Phase 2NCT05256290Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsBlack Diamond Therapeutics, Inc. · Non-Small Cell Lung CancerRecruitingBDTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2028Sponsor estimatePhase 2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc. · Glioblastoma (GBM)RecruitingBDTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2022ActualPhase 1NCT04209465A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.Black Diamond Therapeutics, Inc. · Solid TumorTerminatedBDTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner